这是一篇来自已证抗体库的有关人类 CD94的综述,是根据25篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合CD94 抗体。
CD94 同义词: CD94

BioLegend
小鼠 单克隆(DX22)
  • 流式细胞仪; 人类; 图 1a
BioLegend CD94抗体(Biolegend, 305515)被用于被用于流式细胞仪在人类样本上 (图 1a). Cell (2019) ncbi
小鼠 单克隆(DX22)
  • 流式细胞仪; 人类; 表 s1
BioLegend CD94抗体(Biolegend, DX22)被用于被用于流式细胞仪在人类样本上 (表 s1). Proc Natl Acad Sci U S A (2018) ncbi
小鼠 单克隆(DX22)
  • mass cytometry; 人类; 图 4f
BioLegend CD94抗体(Biolegend, DX22)被用于被用于mass cytometry在人类样本上 (图 4f). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆(DX22)
  • 流式细胞仪; 人类; 图 5a
BioLegend CD94抗体(BioLegend, DX22)被用于被用于流式细胞仪在人类样本上 (图 5a). Proc Natl Acad Sci U S A (2017) ncbi
小鼠 单克隆(DX22)
  • 流式细胞仪; 人类; 图 1a
BioLegend CD94抗体(BioLegend, DX22)被用于被用于流式细胞仪在人类样本上 (图 1a). Nat Immunol (2016) ncbi
小鼠 单克隆(DX22)
  • 流式细胞仪; 人类; 图 1a
BioLegend CD94抗体(biolegend, DX22)被用于被用于流式细胞仪在人类样本上 (图 1a). J Immunol (2016) ncbi
赛默飞世尔
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 s2
赛默飞世尔 CD94抗体(eBioscience, 17-5094-42)被用于被用于流式细胞仪在人类样本上 (图 s2). BMC Cancer (2019) ncbi
小鼠 单克隆(DX22)
  • 流式细胞仪; 人类; 图 1e
赛默飞世尔 CD94抗体(eBiosciences, DX22)被用于被用于流式细胞仪在人类样本上 (图 1e). J Immunol (2016) ncbi
美天旎
人类 单克隆(REA113)
  • 流式细胞仪; 人类; 图 6b
美天旎 CD94抗体(Miltenyi Biotec, REA113)被用于被用于流式细胞仪在人类样本上 (图 6b). Front Immunol (2017) ncbi
贝克曼库尔特实验系统(苏州)有限公司
小鼠 单克隆(HP-3B1)
  • 流式细胞仪; 人类; 表 3
贝克曼库尔特实验系统(苏州)有限公司 CD94抗体(Beckman Coulter (Immunotech), HP-3B1)被用于被用于流式细胞仪在人类样本上 (表 3). Am J Pathol (2017) ncbi
碧迪BD
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 ex1
碧迪BD CD94抗体(BD Biosciences, HP-3D9)被用于被用于流式细胞仪在人类样本上 (图 ex1). Nature (2019) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 5a
碧迪BD CD94抗体(BD Pharmingen, HP-3D9)被用于被用于流式细胞仪在人类样本上 (图 5a). Front Immunol (2019) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 1d
碧迪BD CD94抗体(BD Pharmingen, HP-3D9)被用于被用于流式细胞仪在人类样本上 (图 1d). J Clin Invest (2017) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 1a
碧迪BD CD94抗体(BD Biosciences, HP-3D9)被用于被用于流式细胞仪在人类样本上 (图 1a). JCI Insight (2017) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 2
碧迪BD CD94抗体(BD Biosciences, HP-3D9)被用于被用于流式细胞仪在人类样本上 (图 2). J Immunol Res (2016) ncbi
小鼠 单克隆(HP-3D9)
  • 抑制或激活实验; 人类; 图 7a
碧迪BD CD94抗体(BD Biosciences, HP-3D9)被用于被用于抑制或激活实验在人类样本上 (图 7a). Nat Commun (2016) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 2d
碧迪BD CD94抗体(BD Biosciences, HP-3D9)被用于被用于流式细胞仪在人类样本上 (图 2d). PLoS ONE (2016) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 st1
碧迪BD CD94抗体(BD, 555889)被用于被用于流式细胞仪在人类样本上 (图 st1). Exp Cell Res (2016) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 4b
碧迪BD CD94抗体(BD, 555888)被用于被用于流式细胞仪在人类样本上 (图 4b). Front Immunol (2015) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 表 s5
碧迪BD CD94抗体(BD Bioscience, HP-3D9)被用于被用于流式细胞仪在人类样本上 (表 s5). Proc Natl Acad Sci U S A (2015) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类
碧迪BD CD94抗体(BD Biosciences, HP-3D9)被用于被用于流式细胞仪在人类样本上. Arthritis Rheumatol (2015) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类
碧迪BD CD94抗体(BD, HP-3D9)被用于被用于流式细胞仪在人类样本上. Genes Immun (2015) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类
碧迪BD CD94抗体(BD Biosciences, HP-3D9)被用于被用于流式细胞仪在人类样本上. Cytotherapy (2015) ncbi
小鼠 单克隆(HP-3D9)
  • 免疫细胞化学; 小鼠
碧迪BD CD94抗体(PharMingen, HP-3D9)被用于被用于免疫细胞化学在小鼠样本上. Hum Pathol (2014) ncbi
小鼠 单克隆(HP-3D9)
  • 流式细胞仪; 人类; 图 1
碧迪BD CD94抗体(BD, HP-3D9)被用于被用于流式细胞仪在人类样本上 (图 1). Cancer Immunol Immunother (2014) ncbi
文章列表
  1. Choi J, Lee E, Kim S, Park S, Oh S, Kang J, et al. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer. BMC Cancer. 2019;19:817 pubmed 出版商
  2. Ardain A, Domingo Gonzalez R, Das S, Kazer S, Howard N, Singh A, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. Nature. 2019;: pubmed 出版商
  3. Lim S, Kim J, Jeon S, Shin M, Kwon J, Kim T, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496 pubmed 出版商
  4. Collins P, Cella M, Porter S, Li S, Gurewitz G, Hong H, et al. Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells. Cell. 2019;176:348-360.e12 pubmed 出版商
  5. Dias J, Boulouis C, Gorin J, van den Biggelaar R, Lal K, Gibbs A, et al. The CD4-CD8- MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8+ MAIT cell pool. Proc Natl Acad Sci U S A. 2018;115:E11513-E11522 pubmed 出版商
  6. Herndler Brandstetter D, Shan L, Yao Y, Stecher C, Plajer V, Lietzenmayer M, et al. Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proc Natl Acad Sci U S A. 2017;114:E9626-E9634 pubmed 出版商
  7. Dias J, Leeansyah E, Sandberg J. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017;114:E5434-E5443 pubmed 出版商
  8. Cottineau J, Kottemann M, Lach F, Kang Y, Vély F, Deenick E, et al. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest. 2017;127:1991-2006 pubmed 出版商
  9. Collins A, Rothman N, Liu K, Reiner S. Eomesodermin and T-bet mark developmentally distinct human natural killer cells. JCI Insight. 2017;2:e90063 pubmed 出版商
  10. Canté Barrett K, Mendes R, Li Y, Vroegindeweij E, Pike Overzet K, Wabeke T, et al. Loss of CD44dim Expression from Early Progenitor Cells Marks T-Cell Lineage Commitment in the Human Thymus. Front Immunol. 2017;8:32 pubmed 出版商
  11. Fromm J, Thomas A, Wood B. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol. 2017;187:304-317 pubmed 出版商
  12. Sairafi D, Stikvoort A, Gertow J, Mattsson J, Uhlin M. Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. J Immunol Res. 2016;2016:5601204 pubmed
  13. Cuff A, Robertson F, Stegmann K, Pallett L, Maini M, Davidson B, et al. Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. J Immunol. 2016;197:4283-4291 pubmed
  14. Kwon H, Choi G, Ryu S, Kwon S, Kim S, Booth C, et al. Stepwise phosphorylation of p65 promotes NF-?B activation and NK cell responses during target cell recognition. Nat Commun. 2016;7:11686 pubmed 出版商
  15. Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, et al. Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. PLoS ONE. 2016;11:e0154737 pubmed 出版商
  16. Bal S, Bernink J, Nagasawa M, Groot J, Shikhagaie M, Golebski K, et al. IL-1?, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol. 2016;17:636-45 pubmed 出版商
  17. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed 出版商
  18. Roan F, Stoklasek T, Whalen E, Molitor J, Bluestone J, Buckner J, et al. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016;196:2051-2062 pubmed 出版商
  19. Günther S, Ostheimer C, Stangl S, Specht H, Mózes P, Jesinghaus M, et al. Correlation of Hsp70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Front Immunol. 2015;6:556 pubmed 出版商
  20. Dimova T, Brouwer M, Gosselin F, Tassignon J, Leo O, Donner C, et al. Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire. Proc Natl Acad Sci U S A. 2015;112:E556-65 pubmed 出版商
  21. Hagberg N, Theorell J, Hjorton K, Spee P, Eloranta M, Bryceson Y, et al. Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:1000-11 pubmed 出版商
  22. Presnell S, Al Attar A, Cichocki F, Miller J, Lutz C. Human natural killer cell microRNA: differential expression of MIR181A1B1 and MIR181A2B2 genes encoding identical mature microRNAs. Genes Immun. 2015;16:89-98 pubmed 出版商
  23. Alnabhan R, Madrigal A, Saudemont A. Differential activation of cord blood and peripheral blood natural killer cells by cytokines. Cytotherapy. 2015;17:73-85 pubmed 出版商
  24. Yu J, Zuo Z, Zhang W, Yang Q, Zhang Y, Tang Y, et al. Identification of immunophenotypic subtypes with different prognoses in extranodal natural killer/T-cell lymphoma, nasal type. Hum Pathol. 2014;45:2255-62 pubmed 出版商
  25. Chang S, Kohrt H, Maecker H. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother. 2014;63:713-9 pubmed 出版商